Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Carbetocin (Duratocin/Pabal) peptide icon, one bubble per amino acidCarbetocin (Duratocin/Pabal)9 residues (approx.)CYIQNCPLGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

Carbetocin (Duratocin/Pabal)

33-55 minutes half-life·Injection

Also known as: Pabal, Duratocin, sdOT

Nearly 30,000 women across 10 countries proved it works. Carbetocin (sold as Pabal in Europe and Duratocin in Canada) is a synthetic oxytocin analog built for one job: preventing postpartum hemorrhage after delivery. One injection. One fixed dose. Sixty minutes of sustained uterine contraction, compared to roughly 15 minutes from standard oxytocin. The CHAMPION trial [1] earned it a spot on the WHO Essential Medicines List in 2019, and it's now approved in over 40 countries. The catch: the FDA hasn't approved it, so US patients don't have access. For the rest of the world, it's become a cornerstone of obstetric care.

What Is Carbetocin (Duratocin/Pabal)?

One injection, sixty minutes of protection. That's the clinical pitch for carbetocin, an octapeptide synthetic analog of oxytocin (CAS 37025-55-1) marketed as Pabal in Europe and Duratocin in Canada.

The structural trick is simple on paper but took decades to engineer. Replacing the native disulfide bridge with a thioether linkage and deaminating the cysteine at position 1 makes the molecule resistant to oxytocinase, the enzyme that chews through natural oxytocin in minutes. The result: a half-life of 33 to 55 minutes depending on route, compared to oxytocin's 3 to 5 minutes.

Clinicians use it for exactly one thing. After delivery of the infant, a single 100 mcg dose (IV for cesarean, IM for vaginal birth) triggers sustained rhythmic uterine contractions that prevent the uterine atony responsible for most postpartum hemorrhage. No titration. No infusion pump. No repeat dosing.

The evidence base is strong. The WHO-led CHAMPION trial enrolled 29,645 women across 23 sites in 10 countries and confirmed non-inferiority to oxytocin 10 IU IM for preventing blood loss of 500 mL or greater after vaginal birth [1]. A 2025 systematic review covering 30 publications found carbetocin superior to misoprostol on blood loss outcomes (PMC12145113). Multiple RCTs in cesarean settings show it reduces the need for rescue uterotonics by 30 to 50 percent.

Carbetocin holds approval in over 40 countries, including EU member states, Canada, Australia, and Singapore. The heat-stable formulation, which doesn't need refrigeration below 30 degrees Celsius, landed on the WHO Essential Medicines List in 2019. The FDA has not approved carbetocin; it remains classified as a research compound in the US market.

How Carbetocin (Duratocin/Pabal) Works

Carbetocin binds the oxytocin receptor (OXTR), a Gq-coupled receptor packed densely across myometrial smooth muscle during late pregnancy and the immediate postpartum window. Receptor activation triggers phospholipase C-beta, which hydrolyzes PIP2 into IP3 and DAG. IP3 dumps calcium from the sarcoplasmic reticulum; DAG fires up protein kinase C. Both pathways converge on actin-myosin cross-bridge cycling to produce sustained contraction.

Two things set carbetocin apart from oxytocin at the receptor level. First, it's a functionally selective Gq agonist with minimal activity at vasopressin V1a or V1b receptors [2]. That selectivity likely explains the slightly cleaner cardiovascular profile.

Second, and this is the mechanistic detail that matters most clinically, carbetocin triggers beta-arrestin-independent internalization of the OXTR. Once the receptor pulls inside the cell, it stays there. It does not recycle back to the membrane the way it does after oxytocin stimulation. That means the receptor keeps signaling from endosomal compartments while the cell surface clears. Sustained intracellular signaling without desensitization-resensitization cycling; roughly 60 minutes of contractile activity from a single dose.

The structural modifications (deaminated position 1, thioether bridge replacing the disulfide bond) block degradation by oxytocinase and other serum peptidases. Plasma half-life extends 4 to 10 fold over native oxytocin.

An additional contractile pathway runs through COX-2 upregulation. OXTR activation increases local prostaglandin F2-alpha production, adding a calcium-independent myometrial stimulus on top of the direct Gq pathway.

Carbetocin (Duratocin/Pabal) Benefits

  • Carbetocin benefits center on postpartum hemorrhage prevention with a single-dose protocol that eliminates prolonged infusions.
  • Non-inferior to oxytocin for preventing blood loss of 500 mL or greater after vaginal delivery, confirmed in 29,645 women across the CHAMPION trial [1].
  • Sixty minutes of sustained uterine contraction from one injection. Oxytocin's effect fades in roughly 15 minutes, often requiring a continuous IV drip.
  • Reduces the need for rescue uterotonic agents by 30 to 50 percent compared to standard oxytocin protocols in cesarean delivery settings [3].
  • Heat-stable formulation stores at room temperature (below 30 degrees Celsius) for up to 3 years. Cold-chain logistics kill oxytocin in settings without reliable refrigeration; this solves that.
  • Favorable cardiovascular profile. No sustained decrease in left ventricular ejection time, a transient cardiac effect seen with oxytocin bolus dosing.
  • Fixed 100 mcg dose regardless of body weight or route. No titration decisions, no infusion rate calculations. That simplicity matters in low-resource birth settings where trained anesthesia staff may not be present.

Carbetocin (Duratocin/Pabal): Science vs Community Consensus

Science Only
Scientific Evidence
Strong
Based on 9 key studies·Research only

WHO-approved pharmaceutical (40+ countries; EU as Pabal, Canada as Duratocin) for PPH prevention after cesarean or vaginal delivery.

Dosing studied: 100 mcg single dose IV (slow injection over 1 min) or IM: no titration, no repeat dosing
Read the evidence (key study, limitations)

CHAMPION trial (NEJM 2018, n=29,645) demonstrated non-inferiority to oxytocin 10 IU IM for blood loss ≥500 mL and need for additional uterotonics after vaginal birth. 2025 systematic review (PMC12145113, 30 publications) confirms superiority to misoprostol on blood loss outcomes. Single fixed 100 mcg dose is the only approved regimen.

Key Study

CHAMPION trial (NEJM 2018, PMID 29949473, n=29,645); 2025 systematic review of 30 publications (PMC12145113)

Limitations

Not FDA-approved in the US; no US pricing or clinical access. Non-inferiority for harder endpoint (blood loss ≥1,000 mL) not conclusively demonstrated in CHAMPION. Intranasal carbetocin for Prader-Willi Syndrome (Acadia ACP-101 COMPASS Phase 3, n=175) failed September 2025: neuropsychiatric indication not viable. WHO REACH trial (PPH treatment use, not prophylaxis) ongoing with no results published as of October 2026 (ISRCTN92079573).

Community Experience
Weak
3.5/5
Based on 0 consumer reports: hospital-only drug

No community use exists.

Community dosing: Not applicable: hospital-administered only
Read the reports (what users report 3, common issues 3)

Carbetocin is a hospital-only obstetric pharmaceutical with no self-administration, biohacking, or off-label consumer protocols. Zero Reddit/forum activity found across r/peptides, r/TTC, and related communities.

What users report (3)
  • Replaces prolonged oxytocin infusion with a single injection
  • Heat-stable formulation eliminates cold-chain requirement in LMIC settings
  • Reduces need for rescue uterotonic agents by 30–50% vs. standard care
Common issues (3)
  • Not FDA-approved: unavailable to US patients
  • Higher per-dose cost than oxytocin in high-income settings
  • Transient flushing, tachycardia, and hypotension after rapid IV administration
Science-Only Evidence

No community use exists: carbetocin is an IV/IM obstetric pharmaceutical administered exclusively in hospital delivery suites. The science-only classification reflects the complete absence of any self-administration or community-protocol context, not a divergence in scientific opinion.

Carbetocin (Duratocin/Pabal) Dosage Guide

RegulatoryEU/Health Canada-approved Pabal/Duratocin dosing; not FDA-approvedSource (opens in a new tab)
LevelDose / InjectionFrequency
Beginner100 mcgSingle dose
Moderate100 mcgSingle dose
Aggressive100 mcgSingle dose
Note:

Carbetocin comes ready to use. No reconstitution, no BAC water, no math. Each vial or ampoule contains 100 mcg in 1 mL of solution. You draw up the full 1 mL and that's the dose.

For IV (cesarean): push the entire 1 mL slowly over exactly one minute. Not 30 seconds, not a fast bolus. Slow push prevents the transient hypotension that catches people off guard.

For IM (vaginal delivery): inject the full 1 mL into the deltoid or thigh. Bioavailability drops to about 77 percent via IM, but peak uterotonic effect is comparable. IM onset runs slower; expect peak plasma at roughly 30 minutes.

The non-obvious thing most people miss: you cannot give a second dose. The receptor internalizes after carbetocin and won't come back. If the uterus stays boggy past 60 minutes, switch to a completely different drug class.

Heat-stable vials store below 30 degrees Celsius without refrigeration. Standard formulation needs cold chain. Check the vial label.

Cycling

Carbetocin is not used in a cycling protocol. It is administered as a single dose exclusively in the immediate postpartum period to prevent uterine atony and hemorrhage. No repeat dosing or long-term use is indicated. If additional uterotonic support is needed after carbetocin, alternative agents (oxytocin infusion, ergometrine, or prostaglandins) should be used rather than a second dose of carbetocin.

Calculate your Carbetocin (Duratocin/Pabal) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Carbetocin (Duratocin/Pabal) Protocols by Goal

beginnerClinical TrialSingle dose: no cycle, no maintenance phase, no repeat dosing. Pharmacological uterotonic effect lasts ~60 minutes.
IV Administration (Cesarean Section)
Wk N/A: acute single dose
100 mcg (1 mL) · Single dose only: no repeat dosing · Intravenous (slow injection over exactly 1 minute)
IM Administration (Vaginal Delivery)
Wk N/A: acute single dose
100 mcg (1 mL) · Single dose only: no repeat dosing · Intramuscular

Expected: IV onset within 2 min; IM peak effect at ~30 min. Sustained rhythmic uterine contractions for ~60 min. Reduces need for additional uterotonic rescue agents by 30–50% vs. standard care. Non-inferior to oxytocin 10 IU IM for PPH prevention after vaginal birth (CHAMPION trial, n=29,645).

Monitor: Maternal BP and pulse every 15 min for at least 1 hour post-dose. Uterine tone via fundal palpation every 15–30 min. Observe for transient flushing, tachycardia, hypotension (especially after IV). Anaphylaxis monitoring for first 30 min. Quantitative blood loss assessment peripartum.

How to Use Carbetocin (Duratocin/Pabal)

  1. 1
    Confirm delivery of the infant is complete

    Carbetocin is strictly a postpartum agent. Never administer before delivery.

  2. 2
    Step 2

    Draw up the full 1 mL from the single-use 100 mcg/mL vial using a standard syringe. No dilution needed.

  3. 3
    Step 4

    Do not mix carbetocin with other medications in the same syringe.

  4. 4
    Discard any unused portion

    The vial is single-use only. Do not store opened vials.

  5. 5
    Step 6

    Monitor maternal blood pressure and pulse every 15 minutes for at least 1 hour. Palpate the uterine fundus every 15 to 30 minutes to confirm adequate tone.

  6. 6
    Step 7

    If uterine atony persists beyond 60 minutes, do not give a second carbetocin dose. Escalate per institutional PPH protocol: oxytocin infusion, ergometrine, misoprostol, or tranexamic acid.

Step 3 (Cesarean / IV route). With IV access established, inject the full 1 mL slowly over exactly 1 minute. Count it out. Rapid bolus causes transient hypotension and tachycardia. Administer before placental delivery if possible.

Step 3 (Vaginal delivery / IM route). Inject the full 1 mL intramuscularly into the deltoid or lateral thigh. The IM route is preferred when IV access isn't immediately available; bioavailability is approximately 77 percent.

Alternative Routes

Intravenous (slow bolus over 1 min)

100 mcg: identical dose to IM; IV t½ ~33 min (0.55h); faster onset and slightly shorter duration

Must be injected slowly over exactly 1 minute. Rapid bolus causes transient hypotension and tachycardia. Preferred intraoperatively when IV access is already established. Give as dedicated slow push: do not add to IV infusion bag.

Intramuscular

100 mcg: identical dose to IV; IM t½ ~55 min (0.92h); bioavailability ~77%; slower onset, peak plasma at ~30 min

IM route is logistically simpler: no IV line required; important for LMIC birth attendant training. Heat-stable formulation is particularly valuable for IM delivery in settings without cold-chain infrastructure.

Carbetocin (Duratocin/Pabal) Stacking Protocols

Works With

Tranexamic acid (TXA)

Antifibrinolytic increasingly bundled with uterotonics in PPH management. WHO recommends TXA 1 g IV within 3h of PPH onset. Clinical practice uses carbetocin prophylaxis → TXA as treatment escalation in a sequential bundle; not co-administered prophylactically.

TXA 1 g IV at PPH diagnosis (blood loss ≥500 mL or clinical concern); sequential with carbetocin, not co-administered at delivery

Avoid

Atosiban

Atosiban is a competitive oxytocin receptor (OTR) antagonist: directly opposes carbetocin's OTR agonism at the same receptor. Concurrent use negates the uterotonic effect of carbetocin. These agents are pharmacological opposites.

Do not combine
Ergot alkaloids (methylergometrine, ergometrine)

Per Pabal SmPC: may enhance hypertensive effects when used concomitantly with carbetocin. Allow adequate time interval if sequential uterotonic use is required. Particularly relevant for patients with hypertension or pre-eclampsia.

Prostaglandins (misoprostol, dinoprostone)

Per Pabal SmPC: may potentiate uterotonic effect, increasing risk of uterine hyperstimulation. Use as escalation only if carbetocin effect is insufficient, not as routine co-prophylaxis.

Inhalation anesthetics (halothane, sevoflurane)

Per Pabal SmPC: may enhance hypotensive effects and weaken the uterotonic response to carbetocin. Intraoperative clinical vigilance required during cesarean under inhalational anesthesia.

Estimated Cost

Brand Price
Pabal/Duratocin (Ferring): institutional formulary pricing not publicly listed; estimated €8–40 per 100 mcg ampoule (EU/Canada/Australia hospital procurement; wide variation by country and negotiated contract pricing)
Generic / Research
LMIC public sector: $0.31 ±10% per 100 mcg ampoule (Ferring subsidized price for public facilities in low- and lower-middle-income countries, per Ferring public commitment 2019; MPP-licensed generic supply expanding since April 2024)

Pricing updated 2026-04-09

Carbetocin (Duratocin/Pabal) Side Effects

The most serious risk with carbetocin is cardiovascular: transient hypotension and tachycardia after IV administration, reported in 1 to 10 percent of patients per the Pabal SmPC. Rapid IV bolus makes this worse. The drug must be injected slowly over exactly one minute; faster delivery produces clinically meaningful drops in blood pressure.

Carbetocin also carries antidiuretic properties similar to oxytocin. Excessive fluid intake combined with the drug's effects can theoretically cause water intoxication and hyponatremia. The single-dose protocol largely mitigates this, since there's no prolonged infusion pushing free water retention. But it still matters for patients already receiving large-volume IV fluids during delivery.

Serious cardiovascular disorders and cardiac rhythm disturbances are listed contraindications. Carbetocin has not been formally evaluated in eclampsia or severe pre-eclampsia, so it should be used with caution in those populations.

Common side effects (1 to 10 percent incidence) tracked across clinical trials and the Pabal SmPC include headache, tremor, nausea, vomiting, abdominal pain, flushing, feeling of warmth, and metallic taste. Anemia appears in over 10 percent of recipients, though that largely reflects the delivery context itself rather than a direct drug effect.

Uncommon to rare reactions include dizziness, chest pain or tightness, dyspnea, pruritus, and back pain. Allergic or hypersensitivity reactions are rare but documented. Anaphylaxis resuscitation equipment must be immediately available for the first 30 minutes after dosing.

A critical pharmacological safety point: do not repeat the dose. After carbetocin binds the OXTR, the receptor internalizes and does not return to the cell surface. A second dose of carbetocin has no receptor to act on. If uterine atony persists beyond 60 minutes, the correct escalation is a different uterotonic agent (oxytocin infusion, ergometrine, misoprostol, or tranexamic acid) per institutional PPH protocol.

Drug interactions deserve attention in the obstetric setting. Ergot alkaloids (methylergometrine, ergometrine) may amplify hypertensive effects. Prostaglandins (misoprostol, dinoprostone) can potentiate the uterotonic effect and risk uterine hyperstimulation. Inhalation anesthetics (halothane, sevoflurane) may weaken the uterotonic response while worsening hypotension. These interactions are manageable but require awareness during cesarean and complicated vaginal deliveries.

Carbetocin is contraindicated in pregnancy and labor before delivery of the infant. It must never be used for labor induction or augmentation. Significant hepatic or renal impairment reduces clearance and extends the already-prolonged pharmacological effect.

Bottom line on safety: carbetocin has a clean profile for its intended single-dose postpartum use. The risks are real but transient and manageable in a monitored obstetric setting. The drug earns its safety grade through the CHAMPION trial's massive dataset and years of post-marketing surveillance across 40+ countries.

Common Issues & Solutions

Never administer before delivery of the infant: premature use could cause fetal distress and uterine hypertonicity with fetal compromise. Carbetocin is strictly a postpartum agent.

Do not give as rapid IV bolus: inject slowly over exactly 1 minute. Rapid bolus causes transient but clinically significant hypotension and tachycardia. Consider IM route if controlled IV injection rate cannot be guaranteed.

Do not repeat the dose if uterine atony persists: the OXTR undergoes beta-arrestin-independent internalization after carbetocin and does not recycle to the plasma membrane. A second dose has no receptor to act on. Escalate to oxytocin infusion, ergometrine, or misoprostol instead.

In US clinical settings: carbetocin is not FDA-approved and not legally available. Use standard ACOG protocol: oxytocin 10–40 IU in 500–1,000 mL IV infusion after delivery. Do not attempt off-label procurement.

Confirm no significant hepatic or renal impairment before administration: reduced clearance extends an already-prolonged pharmacological effect and increases risk of adverse cardiovascular events.

Ask AI about this page

Ask AI for a second opinion on Carbetocin (Duratocin/Pabal) dosing and side effects

Contraindications

  • Pregnancy and labor before delivery of the infant
  • Use for labor induction (not indicated)
  • Hypersensitivity to carbetocin, oxytocin, or any excipients
  • Significant hepatic impairment (reduced clearance)
  • Significant renal impairment
  • Serious cardiovascular disorders, particularly cardiac rhythm disorders
  • Epilepsy
  • Eclampsia or severe pre-eclampsia (use with caution, safety not formally evaluated)

Drug Interactions

  • Ergot alkaloids (e.g., methylergometrine): may enhance hypertensive effects when used concomitantly; allow adequate time interval if sequential use is required
  • Prostaglandins (e.g., misoprostol, dinoprostone): may potentiate the uterotonic effect of carbetocin, increasing risk of uterine hyperstimulation
  • Inhalation anesthetics (e.g., halothane, sevoflurane): may enhance hypotensive effects and weaken the uterotonic response of carbetocin
  • Other oxytocic agents: concurrent use is not recommended; use alternative uterotonics only as rescue therapy if carbetocin alone is insufficient
  • Caudal/epidural anesthesia with vasoconstrictors: potential for enhanced hypertensive response when combined with carbetocin

Product Quality

Recommended Monitoring

TestWhenTarget
Maternal blood pressure and heart rateEvery 15 minutes for at least 1 hour post-doseBP >90/60 mmHg; HR <100 bpm
Uterine tone (fundal palpation and height assessment)Every 15–30 minutes post-deliveryFirm, well-contracted uterus at or below umbilical level within 1 hour of delivery
Quantitative blood loss estimationContinuous peripartum and for at least 2 hours post-delivery<500 mL for vaginal delivery; <1,000 mL for cesarean section
Hypersensitivity / anaphylaxis surveillanceFirst 30 minutes post-dose; anaphylaxis resuscitation equipment must be immediately availableNo urticaria, bronchospasm, angioedema, or hemodynamic collapse
Maternal blood pressure and heart rate

Transient hypotension and tachycardia are common ADRs (1–10% per Pabal SmPC), particularly after IV administration

Uterine tone (fundal palpation and height assessment)

Confirm adequate uterotonic response; identify persistent uterine atony requiring escalation to additional uterotonics

Quantitative blood loss estimation

Primary endpoint of PPH prevention; defines threshold for escalation therapy (≥500 mL or hemodynamic compromise)

Hypersensitivity / anaphylaxis surveillance

Rare but serious allergic/hypersensitivity reactions reported with carbetocin (Pabal SmPC Section 4.4)

Carbetocin (Duratocin/Pabal) Before and After

0-2 minutes

Onset of uterotonic activity with initial uterine contraction following IV administration

2-30 minutes

Peak uterotonic effect with sustained rhythmic uterine contractions; peak plasma concentration reached (IM)

30-60 minutes

Continued uterine contractile activity; plasma levels declining but pharmacological effect maintained

1-2 hours

Uterotonic effect waning; uterine tone stabilized in most patients; drug largely eliminated

What to Expect

0 to 2 minutes: The uterotonic effect kicks in fast after IV injection. Initial contraction begins within two minutes. IM onset runs slower, with peak plasma levels not arriving until around 30 minutes. Flushing, warmth, and headache are common at this stage, especially with the IV route.

2 to 30 minutes: Peak contractile activity. The uterus settles into sustained rhythmic contractions. IM recipients hit peak plasma concentration around the 30-minute mark. Transient tachycardia, hypotension, nausea, abdominal pain, and metallic taste may appear in 1 to 10 percent of patients. These effects are brief.

30 to 60 minutes: Plasma levels are falling, but the uterotonic effect holds. The reason is pharmacological, not pharmacokinetic. The OXTR has internalized and keeps signaling from inside the cell. IV half-life is about 33 minutes; IM half-life about 55 minutes. Side effects are generally fading. Abdominal cramping may linger.

1 to 2 hours: The drug is mostly cleared. Uterine tone has stabilized in most patients. The OXTR stays internalized, so the contractile response doesn't snap back abruptly. If the uterus is still boggy at this point, carbetocin's window is closed. Time to escalate to a different agent.

Detailed Timeline: Science vs Community

0–2 minutes
Science

Onset within 2 min of IV administration; initial uterine contraction begins. IM onset is slower: peak plasma concentration reached at ~30 min.

Community

N/A: hospital setting only

2–30 minutes
Science

Sustained rhythmic uterine contractions. IM peak plasma concentration at ~30 min. Maximum contractile activity. IV plasma levels declining but OXTR-mediated signaling sustained via endosomal compartments.

Community

N/A

30–60 minutes
Science

Continued uterine contractile activity as plasma levels decline. Pharmacological effect maintained via sustained intracellular signaling from internalized OXTR (endosomal pathway). IV t½ ~33 min; IM t½ ~55 min.

Community

N/A

1–2 hours
Science

Uterotonic effect waning; uterine tone stabilized. Drug largely eliminated. OXTR remains internalized: receptor does not rapidly recycle; uterine response does not abruptly return.

Community

N/A

Pharmacokinetics

Half-Life
33min
Bioavailability
IM: ~77%
Tmax
IM: ~30 minutes; IV: immediate
Data Confidence
high

Source: Pabal SmPC (UK EMC): geometric mean terminal half-life: 33 min IV, 55 min IM

Pharmacokinetics: Active Dose Over Time

t½ = 33-55 minutes (IV: ~33 min, IM: ~55 min)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
9
Structure
Cyclic
Sequence
CYIQNCPLG
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider Carbetocin (Duratocin/Pabal)

  • Postpartum women after cesarean section
  • Postpartum women after vaginal delivery
  • Women at risk of uterine atony
  • Obstetric patients in low-resource settings without cold-chain infrastructure
  • Women with contraindications to ergometrine (hypertension, pre-eclampsia)

Related Peptides

What Changed for Carbetocin (Duratocin/Pabal)

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 8, 20269 Citations

References

  1. [1]Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth (CHAMPION Trial) (opens in a new tab)PubMed (opens in a new tab)Clinical Trial
  2. [2]Carbetocin is a Functional Selective Gq Agonist That Does Not Promote Oxytocin Receptor Recycling After Inducing Beta-Arrestin-Independent Internalisation (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section (opens in a new tab)PubMed (opens in a new tab)Clinical Trial

Related Tools

Storage & Stability

Before Reconstitution
Up to 3 years at controlled room temperature (below 30°C), protected from light
After Reconstitution
Use immediately after opening; single-use vial, do not store opened vials
Temperature
Below 30°C (86°F); do not freeze

Frequently Asked Questions

Carbetocin (Pabal/Duratocin) is approved in 40+ countries; including EU member states, Canada, Australia, and the WHO Essential Medicines List; for prevention of postpartum hemorrhage (PPH) after cesarean or vaginal delivery. It is not FDA-approved in the United States.

Carbetocin's dose is fixed at 100 mcg regardless of body weight or route. Its prolonged receptor internalization mechanism means a single dose provides ~60 minutes of uterotonic activity; repeat dosing adds risk without additional benefit. The CHAMPION trial established this as the global standard.

Carbetocin has a 4–10x longer half-life than oxytocin, can be given as a single injection rather than a continuous infusion, and does not require cold-chain storage in its heat-stable formulation. The CHAMPION trial (n=29,645) demonstrated non-inferiority to oxytocin 10 IU IM for PPH prevention after vaginal birth.

No. Carbetocin is contraindicated for labor induction or augmentation. It is strictly a postpartum agent; it must only be administered after delivery of the infant.

The heat-stable formulation maintains efficacy up to 30°C for 3 years without refrigeration. This is critical in low-resource settings where cold-chain infrastructure for oxytocin is unreliable. WHO added heat-stable carbetocin to its Essential Medicines List in 2019 specifically because of this advantage.